Tags

Type your tag names separated by a space and hit enter

Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials.
J Ocul Pharmacol Ther. 2013 Nov; 29(9):837-41.JO

Abstract

PURPOSE

To evaluate pill counts and red blood cell (RBC) membrane fatty acid profiles as measures of compliance with oral omega3 polyunsaturated fatty acids (ω3 PUFAs) and to compare the two techniques.

METHODS

Sixteen dry eye disease subjects were given oral ω3 PUFA or placebo for 3 months. Compliance was measured by pill counts and blood tests at baseline and 3 months. The Wilcoxon signed-rank tests and rank-sum tests were used to compare changes from baseline and the difference between the two groups; Spearman correlation coefficients were used to assess the relationship of pill counts to changes in blood FAs.

RESULTS

Pill counts for the ω3 (n=7) and placebo (n=9) groups showed a mean consumption of 4.39 and 4.76 pills per day, respectively. In the ω3 group, the median change from baseline was +1.46% for eicosapentaenoic acid (EPA) (P=0.03), +1.49% for docosahexaenoic acid (DHA) (P=0.08), and -1.91% for arachidonic acids (AA) (P=0.02). In the placebo group, median changes in all measured FAs were small and not statistically significant. The difference in change in FA levels between the two groups was significantly greater for EPA (P=0.01) and AA (P=0.04). The correlations between pill counts and changes in EPA (r=0.36, P=0.43) and DHA (r=0.17, P=0.70) were not strong.

CONCLUSIONS

RBC FA analysis can be used to measure compliance in the active group and also monitor the placebo group for nonstudy ω3 intake. Low correlation of pill counts with blood levels suggests that pill counts alone may be inaccurate and should be replaced or supplemented with objective measures.

Authors+Show Affiliations

1 Department of Ophthalmology, Mount Sinai School of Medicine , Mount Sinai Medical Center, New York, New York.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23971620

Citation

Gadaria-Rathod, Neha, et al. "Red Blood Cell Fatty Acid Analysis for Determining Compliance With Omega3 Supplements in Dry Eye Disease Trials." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 29, no. 9, 2013, pp. 837-41.
Gadaria-Rathod N, Dentone PG, Peskin E, et al. Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials. J Ocul Pharmacol Ther. 2013;29(9):837-41.
Gadaria-Rathod, N., Dentone, P. G., Peskin, E., Maguire, M. G., Moser, A., & Asbell, P. A. (2013). Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 29(9), 837-41. https://doi.org/10.1089/jop.2013.0043
Gadaria-Rathod N, et al. Red Blood Cell Fatty Acid Analysis for Determining Compliance With Omega3 Supplements in Dry Eye Disease Trials. J Ocul Pharmacol Ther. 2013;29(9):837-41. PubMed PMID: 23971620.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials. AU - Gadaria-Rathod,Neha, AU - Dentone,Peter G, AU - Peskin,Ellen, AU - Maguire,Maureen G, AU - Moser,Ann, AU - Asbell,Penny A, Y1 - 2013/08/24/ PY - 2013/8/27/entrez PY - 2013/8/27/pubmed PY - 2014/8/2/medline SP - 837 EP - 41 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 29 IS - 9 N2 - PURPOSE: To evaluate pill counts and red blood cell (RBC) membrane fatty acid profiles as measures of compliance with oral omega3 polyunsaturated fatty acids (ω3 PUFAs) and to compare the two techniques. METHODS: Sixteen dry eye disease subjects were given oral ω3 PUFA or placebo for 3 months. Compliance was measured by pill counts and blood tests at baseline and 3 months. The Wilcoxon signed-rank tests and rank-sum tests were used to compare changes from baseline and the difference between the two groups; Spearman correlation coefficients were used to assess the relationship of pill counts to changes in blood FAs. RESULTS: Pill counts for the ω3 (n=7) and placebo (n=9) groups showed a mean consumption of 4.39 and 4.76 pills per day, respectively. In the ω3 group, the median change from baseline was +1.46% for eicosapentaenoic acid (EPA) (P=0.03), +1.49% for docosahexaenoic acid (DHA) (P=0.08), and -1.91% for arachidonic acids (AA) (P=0.02). In the placebo group, median changes in all measured FAs were small and not statistically significant. The difference in change in FA levels between the two groups was significantly greater for EPA (P=0.01) and AA (P=0.04). The correlations between pill counts and changes in EPA (r=0.36, P=0.43) and DHA (r=0.17, P=0.70) were not strong. CONCLUSIONS: RBC FA analysis can be used to measure compliance in the active group and also monitor the placebo group for nonstudy ω3 intake. Low correlation of pill counts with blood levels suggests that pill counts alone may be inaccurate and should be replaced or supplemented with objective measures. SN - 1557-7732 UR - https://www.unboundmedicine.com/medline/citation/23971620/Red_blood_cell_fatty_acid_analysis_for_determining_compliance_with_omega3_supplements_in_dry_eye_disease_trials_ L2 - https://www.liebertpub.com/doi/10.1089/jop.2013.0043?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -